Cargando…

Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report

Immune checkpoint inhibitors (ICIs) are currently approved for a variety of cancers and their use is expanding from advanced disease to first-line metastatic and adjuvant therapies. With the wide application of immunotherapy, its adverse reactions are also the object we need to pay attention to. Amo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shiwei, Ma, Guikai, Wang, Hui, Yu, Guohua, Chen, Jun, Song, Wenjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678624/ https://www.ncbi.nlm.nih.gov/pubmed/36401466 http://dx.doi.org/10.1097/MD.0000000000031873

Ejemplares similares

Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report
por: Wang, Chen, et al.
Publicado: (2023)

Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review
por: Song, Wenjing, et al.
Publicado: (2020)

An unusual huge thymoma composed of sclerosing thymoma and type AB thymoma: A case report
por: Jiang, Yu-ting, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs
por: Hirata, Aya, et al.
Publicado: (2021)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Case Report of Thymoma Tumor Reduction Following Plasmapheresis
por: Jiang, Wei, et al.
Publicado: (2015)

Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy
por: Yoo, Shin Hye, et al.
Publicado: (2017)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report
por: An, Gaili, et al.
Publicado: (2023)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma
por: Carretero-González, Alberto, et al.
Publicado: (2019)

Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report
por: Wen, Yan-Ping, et al.
Publicado: (2022)

Graft-versus-host disease-like erythroderma: a sign of recurrent thymoma: A case report
por: Gui, Xiujuan, et al.
Publicado: (2017)

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
por: Gao, Loulu, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
por: Pu, Dan, et al.
Publicado: (2020)

Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study
por: Rai, Pragya, et al.
Publicado: (2021)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study
por: Zhang, Xu, et al.
Publicado: (2022)

Lung metastasis from thyroid cancer: A case report of unusual imaging presentation of lung metastases
por: Song, Wenjing, et al.
Publicado: (2023)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors
por: Liu, Na, et al.
Publicado: (2022)

The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy
por: Wang, Fei, et al.
Publicado: (2021)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

A new immune checkpoint-associated nine-gene signature for prognostic prediction of glioblastoma
por: Jin, Xiao, et al.
Publicado: (2023)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Cardiotoxicity risk factors with immune checkpoint inhibitors
por: Brumberger, Zachary L., et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1trfpp9icjg7fb338gtfu59m3q